Mallinckrodt PLC (MNK) - NYSE
  • Fri, Jul. 1, 10:08 AM
    • Invitae (NYSE:NVTA) initiated with Hold rating with an $8.50 (18% upside) price target by Benchmark.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Outperform rating and $190 (33% upside) price target by BMO.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Underperform rating and $36 (4% upside) price target by BMO.
    • Mallinckrodt (NYSE:MNK) initiated with Outperform rating and $84 (35% upside) price target by BMO.
    • Horizon Pharma plc (NASDAQ:HZNP) initiated with Outperform rating and $29 (71% upside) price target by BMO.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) initiated with an Outperform rating and $400 (13% upside) price target by Bernstein.
    • Biogen (NASDAQ:BIIB) initiated with an Outperform rating and $282 (15% upside) price target by Bernstein.
    • Amgen (NASDAQ:AMGN) initiated with Market Perform rating and $161 (5% upside) price target by Bernstein.
    • Lannett Company (NYSE:LCI) initiated with Hold rating and $26 (5% upside) price target by Deutsche Bank.
    • OpGen (NASDAQ:OPGN) initiated with Buy rating and $2.50 (66% upside) price target by Rodman & Renshaw.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Market Perform rating and $26 (22% upside) price target by BMO.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $80 (75% upside) price target by H.C. Wainwright.
    • Healthstream (NASDAQ:HSTM) initiated with Outperform rating and $30 (12% upside) price target by Barrington Research.
    • Neurometrix (NASDAQ:NURO) initiated with Buy rating and $4.50 (165% upside) price target by Rodman & Renshaw.
    • Vascular Biogenics (NASDAQ:VBLT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
    | Fri, Jul. 1, 10:08 AM | 6 Comments
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM
  • Wed, May 18, 8:43 PM
    • With the aim of better aligning its financial reporting with its customers and industry peers, Mallinckrodt (NYSE:MNK) changes its fiscal year end to the last Friday in December from the last Friday in September. There will be a transition period from October 1 to December 30, 2016, the results from which will be reported in February 2017.
    | Wed, May 18, 8:43 PM | 2 Comments
  • Tue, May 3, 9:15 AM
    | Tue, May 3, 9:15 AM
  • Tue, May 3, 8:35 AM
    • Mallinckrodt (MNK) FQ2 results: Revenues: $918M (+12.1%); R&D Expense: $58.6M (+1.0%); SG&A: $231.2M (-25.0%); Operating Income: $164.4M (+75.1%); Net Income: $120.3M (+60.0%); EPS: $1.07 (+67.2%); Non-GAAP EPS: $2.01 (+18.2%); Quick Assets: $341.4M (-6.7%); CF Ops: $540.1M (+47.8%).
    • 2016 Guidance: Adjusted EPS: $8.15 - 8.50 from $7.85 - 8.30.
    | Tue, May 3, 8:35 AM | 5 Comments
  • Tue, May 3, 6:03 AM
    • Mallinckrodt (NYSE:MNK): FQ2 EPS of $2.01 beats by $0.29.
    • Revenue of $918M (+12.1% Y/Y) beats by $46.6M.
    • Press Release
    • Shares are up 5% premarket on light volume.
    | Tue, May 3, 6:03 AM
  • Mon, May 2, 5:30 PM
  • Thu, Mar. 17, 7:37 AM
    | Thu, Mar. 17, 7:37 AM
  • Wed, Mar. 16, 2:01 PM
    • Andrew Left's Citron Research's spot-on short call on Valeant Pharmaceuticals (VRX +0.8%) is weighing on Mallinckrodt (MNK -13.3%) , another company Mr. Left says is significantly overvalued and makes Valeant look like a "choirboy" by comparison. Shares have lost over 26% of their value over the past two days.
    • Mallinckrodt depends heavily one product, H.P. Acthar Gel (repository corticosteroid injection) for its growth. In its most recent quarter, fiscal Q1, Acthar generated over 30% ($286.7M/914.8M) of the firm's top line. Mr. Left accuses the company of price gouging, charging $36,000 per vial of Acthar, despite the absence of clinical data that proves its efficacy.
    • A recent example that appears to support Mr. Left's view was the failure of Acthar to show a significant treatment benefit in patients with systemic lupus erythematosus in a label-expanding pilot study run last year.
    • Previously: Mallinckrodt feels Andrew Left's sting; down 17% (Nov. 9, 2015)
    • Previously: Mallinckrodt's Acthar Gel flunks pilot study in Lupus patients (Nov. 9, 2015)
    | Wed, Mar. 16, 2:01 PM | 26 Comments
  • Wed, Mar. 16, 12:50 PM
    | Wed, Mar. 16, 12:50 PM | 2 Comments
  • Tue, Mar. 15, 2:53 PM
    | Tue, Mar. 15, 2:53 PM | 19 Comments
  • Tue, Feb. 2, 6:24 AM
    • Mallinckrodt (MNK +7.3%) FQ1 results: Revenues: $914.8M (+19.1%); R&D Expense: $63.6M (+20.7%); SG&A: $242.5M (+8.2%); Operating Income: $179.4M (+47.5%); Net Income: $115.9M (+32.6%); EPS: $1.00 (+35.1%); Non-GAAP EPS: $2.09 (+16.8%); Quick Assets: $521.9M (+42.6%).
    • 2016 Guidance: Adjusted EPS: $7.85 - 8.30 from $7.70 - 8.20.
    | Tue, Feb. 2, 6:24 AM | 6 Comments
  • Tue, Feb. 2, 6:02 AM
    • Mallinckrodt (NYSE:MNK): FQ1 EPS of $2.09 beats by $0.32.
    • Revenue of $914.8M (+19.1% Y/Y) beats by $26.47M.
    | Tue, Feb. 2, 6:02 AM
  • Mon, Feb. 1, 5:30 PM
    | Mon, Feb. 1, 5:30 PM | 9 Comments
  • Tue, Jan. 5, 10:44 AM
    • With the aim of grabbing some of Mallinckrodt's (MNK +1.9%) Acthar business, ANI Pharmaceuticals (ANIP +2.7%) buys two New Drug Applications (NDAs) from a Dutch subsidiary of Merck (MRK +1.2%) for purified corticotropin gel and corticotropin zinc hydroxide for $75M in cash plus a percentage of future sales.
    • H.P. Acthar Gel (repository corticotropin injection) accounted for $274.2M of Mallinckrodt's fiscal Q4 revenues of $882.4M (31%). It is indicated for the treatment of infantile spasms, multiple sclerosis, systemic lupus erythematosus, allergic and inflammatory ophthalmic processes and other conditions.
    | Tue, Jan. 5, 10:44 AM
  • Dec. 29, 2015, 5:42 PM
    • Top gainers, as of 5.25 p.m.: CREE +2.0%. SDRL +1.9%. FCS +0.8%. XIV +0.6%.
    • Top losers, as of 5.25p.m.: CHK -3.3%. MNK -2.9%. BCEI -2.3%. CMRX -1.4%.
    | Dec. 29, 2015, 5:42 PM | 6 Comments
Company Description
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: Ireland